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EARLY GRAFT FUNCTION AND CYCLOSPORIN 
Alphos Toyotome, Paul Terasaki, Howard Takiff, Barry Kahan, Thomas Starzl, 
Oscar Salvatierra, Thomas Berne and John Najarian. 
In our studies to date, we have used patient and graft survival as 
,the main end point. Although it is true that ultimately these measures 
are the most important, daily serum creatinine values obtained in the 
first month after transplantation may be a helpful indicator of long 
term function -as will be shown here. They should also be of importance 
in measuring the effectiveness of various protocols of immunosuppression. 
We attempt in this chapter to utilize early function data from a 
small subset of patients gathered from five different centers. As a 
trial, data was gathered, computer programs written, and cyclosporin 
dosages and levels were examined. 
METHODS 
Detailed daily data was collected for the first 60 days after 
transplantation from R~9 patients at fjve c~nters for this trial. The 
patient population was selected as much as possible from transplants 
which were performed consecutively within a center and during the same 
time period (1981-1985) between centers so as to obtain a representative 
sample of most transplants being performed. The centers that partici-
pated in this trial were the University of Texas at Houston; University 
of Minnesota; University of California, San Francisco; University of 
Pittsburgh; and the University of Southern California. For this initial 
analysis the serum creatinine, cyclosporin serum levels, and cyclosporin, 
prednisone, Imuran, Solu-Medrol and ATG/ALG dosages were used. By cross-
referencing these data with the transplant registry file, studies on 
patient survival and matching were done. Rejection episodes were either 
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indicated by the centers or retrospectively assigned on the basis of 
an increase in serum creatinine, use of Solu-Medrol, recycling of prednisone, 
use of ATG, increased cyclosporin dosage and biopsy results. Cases with 
questionable rejections were excluded from this portion of the study. 
RESULTS 
The results are presented in the "following figures and legends. 
Figurel. The striking difference in serum creatinine values for 
cadaver transplants in comparison with living-related donors is shown in 
the first 20 days after transplantation. Much of the difference represents 
the effect of ischemic damage to kidneys from cadavers. It is interesting 
to "note, however, that histocompatibility differences between the two 
haplotype-identical HLAJidentical siblings and the one-haplotype-identical 
parental transplants show ,a difference in average serum creatinine 
values from the third day on. The serum creatinine values of cadaver 
donor transplants reach a level of 3 mg/dl around 20 days after transplantation, 
which is higher than that for parental or HLA-identical sibling donor 
transplants. 
Figure 2. When cadaver donor transplants were divided into those 
who were clinically doing well (ranks A or B), and those who were clinically 
doing poorly (ranks C or D), at one year post transplant, retrospective 
. 
analysis of average serum creatinine values shows that the two groups 
had started out quite differently and that the average serum creatinine 
was higher even at day five for those transplants that were classified 
as functioning poorly at one year. Patients having good transplant 
function with clinical ranks of A or B at one year had lower serum 
creatinine values immediately after transplantation with levels of about 
2.0 mg/dl at one month. Patients with poorly functioning kidneys at one 
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year had, at one month, an average serum creatinine slightly over 3.0 
mg/dl. We can conclude that serum creatinine values, even as early as 
--
the fifth day post transplantation, are different in patients who 
ultimately had better or worse kidney function. 
Figure 3. Patients who had serum creatinine levels under 2.5 mg/dl 
on the fifth day after transplantation were shown here to have higher 
graft ~urvival rates than patients who had serum creatinines of more 
than 2.5 mg/dl on the fifth day post transplant. Thus, survival as well 
as clinical ranks as shown in the previous figure, appears to be correlated 
with the early serum creatinine level in cada~er donor transpl~ntsK 
Figure 4. The one year graft survival rate of.cadaver donor transplants 
is given here in relation to the serum creatinine levels on each of the 
p~stoperative days indicated. Thus, the upper line shows the one year 
graft survival rate of patients who had a serum creatinine of 0-2.4 
mg/dl on post transplant day 0 to day 20. It can be noted that those 
patients who had such low serum creatinine values during the first 20 
days postoperatively had one year graft survival rates that were over 
80%. However, those patients having less favorable serum creatinine 
values during the first 20 days post transplantation clearly had a lower 
one year graft survival rate. Those patients who had high serum creatinine 
levels of over 7.5 mg/dl in the early postoperative period t~nded to 
have good one year graft survival rates over 75%, but if high serum 
creatinine levels were obtained after the fifth postoperative day, the 
one year graft survival rate was low. The serum creatinine level after 
the sixth day correlated fairly well with the ultimate one year graft 
survival rate.· 
Figure 5. The average serum creatinine levels of patients who do 
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not experience rejection during the first 60 days is se~n to be lower 
-
than those who did have a rejection as might be expected. Among those 
who do not experience rejection, the average serum creatinine level 
comes down to a level of 2.5 mg/dl at about the 20th day and to 2.0 
mg/dl at about the 50th day. 
Figure ~K The peak number of patients who experience a rejection is 
noted to be.on the seventh day after transplantation. The majority of 
the first rejections occur within two weeks. When larger numbers of 
patients are available for study, this curve can be better defined. 
Figure 7. Average serum creatinine levels of patients who receive 
transplants that ar~ zero or one A,B antigen mismatched show a lower 
level than the average in patients who have two to four HLA-A,B antigens 
mismatched. In the better matched transplants average serum creatinines 
of 2.0 mg/dl are reached two weeks after transplantation. 
Figure 8. Cadaver donor transplants that were mismatched for zero 
or one antigen in the B,DR 10c; had only a slightly lower serum creatinine 
level than patients who were mismatched for two to four B,DR antigens. 
Note the small number of patients available with zero or one B,DR mismatches~ 
Figure 9. Patients who were mismatched for zero, one or two DR 
antigens, had essentially the same average serum creatinine levels. 
Figure 10. Among cadaver donor patients who had zero or one A,B,DR 
mismatch, the average serum creatinine levels were lower than those who 
had two to six antigens mismatched. Again, the number of well matched 
patients was low. 
Figure 11. The average serum creatinine levels for patients who 
received cadaver donor transplants at four different centers were generally 
concordant. The data from center 4 was based on a small number of 
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patients (16) who tended to have a higher serum creatinine level during 
the first two weeks after transplantation;Sy one month, patients at all 
4 centers had similar serum creatinine values. 
Figure 12. The one year graft survival rates of patients at the 
four different centers did not correlate exactly with the early serum 
creatinine levels at the four centers (Fig.i1l). Center 4, which had the 
highest serum creatinine levels, had the highest one year,graft survival 
rate and center 3, which had the best serum creatinine levels, had the 
lowest one year graft survival rate. No conclusions can be drawn from 
the small numbers except to note that comparisons between centers may 
yield valuable information on the most effective protocols for treatment 
of patients. 
Figure 13. The cumulative percent rejection rate for the 4 centers 
encompassed a fairly large range from 30% rejection at 50 days to about 
60%. It would be of interest to correlate the rejection rate with one 
year survival, with function, and with immunosuppressive regimens. 
Protocols by which rejections, or at least conventionally recognized 
rejections, are not seen at all are the ideal. Here, 40% to 70% of 
patients are seen not to have any rejection in the first 50 days. 
Figure, 14. In the same four centers, a comparison of the average 
total daily cyclosporin dose was quite different. Center 2 used a distinctly 
higher early cyclosporin dose for the first 40 days after transplantation. 
Their one year graft survival rate was higher than in center 1 or 3 
which had used lower initial cyclosporin doses. Certainly, this is only 
a measure of one factor involved in this complex procedure. 
Figure 15. The average cyclosporin dose given during the first 
month after transplantation can be seen to be higher for the cadaver 
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donor transplants than living-related donor grafts. Despite the use of 
lower levels of cyclosporin, there was a greater lowering of the serum 
creatinine values in the living-relat~~ donor transplants than ;n the 
cadaver donor transplants (Fig. 1). 
Figure 16. The average cyclosporin dosage given to patients did not 
appear to corr~late with whether the patients had rejections or not. 
When the patients were divided into those who 'had rejected and those who 
did not, the average cyclosporin dosage was quite similar for the first 
60 days. Further division of rejection patients resulted in some differenee 
as shown in the next figure. 
Figure 17. Among. patients with nO.rejection episodes, 'the cyclosporin' 
dosages per day were as shown. These patients could not be distinguished 
; n the fi rs t 10 days fro.m those who had a reject; on epi sode wi thi n the 
first 10 days. eowever~ those who rejected in 11-60 days had a lower 
cyclosporin dosage in the first 10 days. It would seem from these relatively 
small numbers of patients that dosages of cyclosporin lower than a 
tapering of 18 mg/kg/day to 12 mg/kg/day by the 20th days results in 
more rejection after the first 10 days. 
Figure 18. The average daily cyclosporin levels .were plotted for 
patients who had rejections and those who did not. As shown here, the 
average cyclosporin level was slightly lower for those patients who had 
rejected than those who did not. There is a tendency to have increasing 
cyclosporin levels up to day 15. 
Figure 19. The cyclosporinserum level on day 5 was associated with 
the serum creatinine values through the 15th postoperative day. That is, 
. patients who had a low cyclosporin level 0-75 ng/ml on the 5th day had 
the lowest serum creatinine levels. Those patients who had high day 5 
cyclosporin levels.of more than 200 ng/ml had the highest serum creatinine 
levels. These relationships might be the opposite of what we might 
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expect if we assumed that higher levels would be associated with more 
effective immunosuppression. These findings appear to be more consistent 
with early cyclosporin to~icity within the first 15 days. 
Figure 20. The cyclosporin level on day 5 is compared with eventual 
graft survival. Intermediate levels of 76 to 200 mg/ml had the highest 
one year graft survival rate while the lowest survival rate was associated 
with patients who had cyclosporin levels greater than 200 mg/ml on day 
5. However, at three years post transplant, the differences were small. 
DISCUSSION 
The trial described here suggests that a great deal could be learned 
from mu1ticenter analyses of daily data .. Different ilTl11unosuppression 
protocols can be examinedin.detail and compared. We describe here only 
the simple first level analysis. 
Even with these simple analyses, we were quite interested to see 
that, for example, serum creatinine values on the fifth day post transplant 
already distinguish between transplants from-HLA-identical sibling 
donors, parental donors, and cadaver donors. The histocompatibility 
influence in transplants can be concluded to occur within five days 
after transplantation- if these results are confirmed in larger numbers 
of patients. With the small numbers available for analysis, even HLA-
A,B,DR matching in cadaver donor transplants seems to have an early 
effect on the serum creatinine levels. 
A clear association with serum creatinine levels during the first 
month after transplantation and eventual outcome of transplants has been 
presented Ecig~ 4). For example, two weeks after transplantation, if the 
serum creatinine is less than 2.4 mg/dl the one year survival rate was 
more than 80% whereas if it was more than 7.5 mg/dl, the one year 
transplant survival rate was under 30%. Intermediate serum creatinine 
----------
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levels led to intermediate graft survival rates. Even one week after 
transplantation, there was already about a 30% one year graft survival 
rate difference between kidneys that had serum creatinine levels less 
than 2.4 mg/dl and more than 7.5 mg/dl. 
It is interesting to see that the average serum creatinine within 
the first 30 days was different at different centers (Fig. 11). This can 
. 
indicate the difference in quality of preservation or types of donors 
utilized for transplant as well as differences in early immunosuppression 
regimens. Within the four centers in the original trial, the average 
serum creatinine levels had reached similar levels in all four centers 
by 30 days. Use of higher cyclosporin dosages at one center (Fig. 14) 
did not result in lower creatinine values at that center or higher long-
term graft survival rates. Obviously other factors must be taken into 
account. 
When comparing between related donor transplants and cadaver donor 
grafts, total daily cyclosporin dosage was less for the living-related 
transplants. In spite of the reduced cyclosporin dosage, the serum 
creatinine levels dropped to lower values in living-related donor grafts. 
There are many opinions on the value of cyclosporin levels. Retrospective 
analysis of the levels in relation to rejections showed that those 
patients without rejections tended to have slightly higher cyclosporin 
levels. Further analysis will be needed to take into account other 
factors. 
We hoped by these studies to show the potential of using daily data 
gathered from many centers. Much of the problem rests in data entry,' 
manipulation a~d analysis, which of course must be done with computers. 
Other ana lys is has been performed by Mi ckey (1) and new programs for 
analysis are being developed. 
SUMMARY 
-9-
1. The average serum creatinine during the first 20 days after transplantation 
was lower in HLA-identical siblings than parental donor tra.!lsp1ants 
suggesting a very early effect of histocompatibility. 
2. In rather small numbers of patients, the daily average serum creatinine 
values were not different with DR mismatching and S,DR mismatching 
but were lower in the better matched transplants for the A,S loci 
and the A,S,DR loci. 
3. The average serum creatinine values in the-first 20 days after 
transplantation were correlated with the one year graft survival 
rates. Those patients with serum creatinines less than 2.4 mg/dl 
had one year graft survival rates of over 80% compared with those 
patients with serum'creatinines above 7.5 mg/d1 after the first 
week who had one year graft survival rates of over 30% less. Intermediate 
serum creatinine values yielded intennediate one year graft survival 
rates. 
4. The cyc1osporin dosage in the first month after transplantation 
varied considerably between the four centers studied here. These 
values were not necessarily correlated with the 'one year graft 
survival rate, average serum creatinines and the cumulative rejection 
rates in this preliminary examination. 
5. Patients who rejected between 11 to 60 days post transplant had 
lower cyclosporin dos~ges than those who rejected early or who 
had no rejections. 
-10-
6. Although firm conclusions cannot be drawn from the small numbers of 
patients included in this study we hope the potential value of this 
type of analysis is shown. 
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